Seagen Inc., a leading biotechnology company headquartered in the United States, is at the forefront of developing innovative cancer therapies. Founded in 1998, Seagen has made significant strides in the oncology sector, particularly in the development of antibody-drug conjugates (ADCs) that target specific cancer cells while minimising damage to healthy tissue. With a strong presence in major operational regions including North America and Europe, Seagen's core products, such as ADCETRIS and PADCEV, are recognised for their unique mechanisms of action and efficacy in treating various types of cancer. The company has established itself as a key player in the biopharmaceutical industry, achieving notable milestones such as FDA approvals and partnerships that enhance its market position. Seagen continues to drive innovation in cancer treatment, aiming to improve patient outcomes worldwide.
How does Seagen Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Seagen Inc.'s score of 82 is higher than 90% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Seagen Inc., headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Pfizer Inc., and as such, it inherits emissions data and climate commitments from its parent organisation. Seagen's climate initiatives are aligned with those of Pfizer Inc., which has set various reduction targets through the Science Based Targets initiative (SBTi) and participates in the Carbon Disclosure Project (CDP). These initiatives aim to enhance transparency and accountability in emissions reporting and reduction efforts. While specific reduction targets for Seagen Inc. are not detailed, the company's commitment to sustainability is reflected in its alignment with Pfizer's broader climate strategies, including participation in initiatives like RE100 and the Race to Zero campaign. As of now, Seagen Inc. has not publicly disclosed its own emissions figures or specific reduction commitments, but it is expected to follow the sustainability framework established by Pfizer Inc. in its ongoing efforts to address climate change.
Access structured emissions data, company-specific emission factors, and source documents
| 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 964,846,000 | - | - | - | - | - | - | - | 000,000,000 | - | - | - | 000,000,000 |
| Scope 2 | 883,814,000 | - | - | - | - | - | - | - | 000,000,000 | - | - | - | 000,000,000 |
| Scope 3 | - | - | - | - | - | - | - | 000,000,000 | 0,000,000,000 | 00,000,000 | 00,000,000 | 000,000,000 | 0,000,000,000 |
Seagen Inc.'s Scope 3 emissions, which increased significantly last year and increased by approximately 821% since 2019, demonstrating supply chain emissions tracking. Most of their carbon footprint comes from suppliers and value chain emissions, with Scope 3 emissions accounting for 77% of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 79% of Scope 3 emissions.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Seagen Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.